Minocycline ( DrugBank: Minocycline )

---

13 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	2
6	Parkinson disease	1
8	Huntington disease	2
13	Multiple sclerosis/Neuromyelitis optica	8
46	Malignant rheumatoid arthritis	2
85	Idiopathic interstitial pneumonia	1
90	Retinitis pigmentosa	2
94	Primary sclerosing cholangitis	1
162	Pemphigoid	1
201	Angelman syndrome	3
206	Fragile X syndrome	4
280	Huge arteriovenous malformation with cervicofacial or limb lesion	1
299	Cystic fibrosis	3

2. Amyotrophic lateral sclerosis

---

Clinical trials : 624 /  Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00355576 (ClinicalTrials.gov)	July 2006	21/7/2006	Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis	Phase II Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: Celecoxib;Drug: Creatine;Drug: Minocycline	Columbia University	ALS Association;Pfizer	Completed	21 Years	85 Years	Both	86	Phase 2	United States
2	NCT00047723 (ClinicalTrials.gov)	January 2003	16/10/2002	Minocycline to Treat Amyotrophic Lateral Sclerosis		Amyotrophic Lateral Sclerosis	Drug: minocycline	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	21 Years	85 Years	Both	400	Phase 3	United States

6. Parkinson disease

---

Clinical trials : 2,298 /  Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00063193 (ClinicalTrials.gov)	May 2003	23/6/2003	National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial	A Multi-center, Double-blind, Pilot Study of Minocycline and Creatine in Subjects With Early Untreated Parkinson's Disease	Parkinson's Disease	Drug: minocycline;Drug: creatine	University of Rochester	National Institute of Neurological Disorders and Stroke (NINDS)	Completed	30 Years	N/A	Both	195	Phase 2	United States

8. Huntington disease

---

Clinical trials : 229 /  Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00277355 (ClinicalTrials.gov)	April 2006	12/1/2006	Pilot Study of Minocycline in Huntington's Disease	A Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntington's Disease	Huntington Disease	Drug: minocycline;Drug: Matching placebo	Merit Cudkowicz	FDA Office of Orphan Products Development	Completed	18 Years	N/A	All	114	Phase 2/Phase 3	United States;Canada
2	NCT00029874 (ClinicalTrials.gov)	September 2001	24/1/2002	Minocycline in Patients With Huntington's Disease	Minocycline Dosing and Safety in Huntington's Disease	Huntington's Disease	Drug: Minocycline	FDA Office of Orphan Products Development	NULL	Completed	18 Years	N/A	Both	63	Phase 1/Phase 2	United States

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04291456 (ClinicalTrials.gov)	January 31, 2020	18/11/2019	Minocycline in MS: Confirmation of Benefit	Open-Label Trial of Minocycline in Early Multiple Sclerosis: Confirmation of Treatment Benefit	Multiple Sclerosis;Clinically Isolated Syndrome	Drug: Minocycline 100mg	University of Calgary	Hotchkiss Brain Institute, University of Calgary	Recruiting	18 Years	60 Years	All	148	Phase 3	Canada
2	NCT01073813 (ClinicalTrials.gov)	February 2010	22/2/2010	Neuroprotection and Repair in Optic Neuritis	Developing Neuroprotection and Repair Strategies in MS: Phase IIa Randomized, Controlled Trial of Minocycline in Acute Optic Neuritis (ON)	Multiple Sclerosis;Optic Neuritis	Drug: Minocycline	University of Calgary	Neuroscience Canada	Terminated	18 Years	60 Years	Both	6	Phase 2	Canada
3	NCT00666887 (ClinicalTrials.gov)	January 2009	23/4/2008	Minocycline in Clinically Isolated Syndromes (CIS)	A Phase III Double-blind, Randomized, Placebo-controlled Trial of Minocycline in Clinically Isolated Syndromes (CIS) and Early Single Relapse Multiple Sclerosis (MS)	Clinically Isolated Syndromes;Early Single Relapse of Multiple Sclerosis	Drug: Minocycline;Drug: Placebo	Dr. Luanne Metz	Multiple Sclerosis Society of Canada	Completed	18 Years	60 Years	All	142	Phase 3	Canada
4	NCT01134627 (ClinicalTrials.gov)	February 2006	28/5/2010	Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline Versus Placebo as Add-on Therapy in Patients Who Are on Treatment With Interferon-beta-1a 44 Mcg Tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Minocycline;Drug: Placebo	Merck KGaA	NULL	Terminated	18 Years	55 Years	All	305	Phase 2	Denmark
5	EUCTR2005-004289-18-FI (EUCTR)	26/01/2006	07/11/2005	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline)	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline)	Relapse Remitting Multiple Sclerosis MedDRA version: 8.0;Level: PT;Classification code 10063399	Product Name: Minocycline 100 mg Film-coated Tablets INN or Proposed INN: Minocycline Hydrochloride	Merck AB	NULL	Not Recruiting			Female: yes Male: yes	320		Finland;Sweden
6	EUCTR2005-004289-18-SE (EUCTR)	04/01/2006	10/11/2005	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline)	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline)	Relapse Remitting Multiple Sclerosis MedDRA version: 8.0;Level: PT;Classification code 10063399	Product Name: Minocycline 100 mg Film-coated Tablets INN or Proposed INN: Minocycline Hydrochloride	Merck AB	NULL	Not Recruiting			Female: yes Male: yes	320		Finland;Sweden
7	EUCTR2005-004289-18-DK (EUCTR)	19/12/2005	28/11/2005	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline)	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline)	Relapse Remitting Multiple Sclerosis MedDRA version: 8.0;Level: PT;Classification code 10063399	Product Name: Minocycline 100 mg Film-coated Tablets INN or Proposed INN: Minocycline Hydrochloride	E. Merck AB	NULL	Not Recruiting			Female: yes Male: yes	320		Finland;Denmark;Sweden
8	NCT00203112 (ClinicalTrials.gov)	June 2004	13/9/2005	Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline	A Multi-Centered, Randomized, Double-Blind, Placebo-Controlled, Parallel Study Assessing the Add-on Effect of Minocycline in Relapsing-Remitting Multiple Sclerosis (RR-MS) Subjects Treated With Glatiramer Acetate (GA).	Relapse Remitting Multiple Sclerosis	Drug: glatiramer acetate with minocycline;Drug: Glatiramer acetate with placebo	Teva Pharmaceutical Industries	NULL	Completed	18 Years	50 Years	Both	44	Phase 2	Canada

Back to top

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,325 /  Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03414502 (ClinicalTrials.gov)	August 2007	2/1/2014	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Abatacept;Drug: Adalimumab;Drug: Azathioprine;Drug: Baricitinib;Drug: Certolizumab;Drug: Etanercept;Drug: Golimumab;Drug: Hydroxychloroquine;Drug: Infliximab;Drug: Leflunomide;Drug: Minocycline;Drug: Rituximab;Drug: Sarilumab;Drug: Sulfasalazine;Drug: Tofacitinib	University of Nebraska	NULL	Recruiting	19 Years	N/A	All	400	Phase 3	United States
2	NCT00579644 (ClinicalTrials.gov)	January 2001	18/12/2007	Treatment of Early RA: Minocycline in Combination With Methotrexate vs Methotrexate Alone	Treatment of Early Rheumatoid Arthritis: Minocycline in Combination With Methotrexate Versus Methotrexate Alone	Rheumatoid Arthritis	Drug: Combination of Minocycline and MTX or MTX alone;Drug: methotrexate	University of Nebraska	NULL	Completed	19 Years	75 Years	All	91	Phase 3	NULL

85. Idiopathic interstitial pneumonia

---

Clinical trials : 598 /  Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00203697 (ClinicalTrials.gov)	April 2006	13/9/2005	Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study	Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study	Idiopathic Pulmonary Fibrosis	Drug: minocycline	University of California, Los Angeles	NULL	Active, not recruiting	20 Years	79 Years	Both		Phase 3	United States

90. Retinitis pigmentosa

---

Clinical trials : 130 /  Drugs : 180 - (DrugBank : 41) / Drug target genes : 49 - Drug target pathways : 109

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04068207 (ClinicalTrials.gov)	February 22, 2019	23/8/2019	Minocycline Treatment in Retinitis Pigmentosa	The Efficacy and Safety of Oral Minocycline in the Treatment of Retinitis Pigmentosa: An Open-label Clinical Trial	Retinitis Pigmentosa;Inherited Retinal Dystrophy;Retina Disorder	Drug: Minocycline	Sun Yat-sen University	NULL	Recruiting	18 Years	60 Years	All	35	Phase 2	China
2	NCT02140164 (ClinicalTrials.gov)	May 2014	14/5/2014	Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa	Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated With Retinitis Pigmentosa	Retinitis Pigmentosa	Drug: Minocycline	National Eye Institute (NEI)	The EMMES Corporation	Completed	12 Years	N/A	All	7	Phase 1/Phase 2	United States

94. Primary sclerosing cholangitis

---

Clinical trials : 142 /  Drugs : 113 - (DrugBank : 37) / Drug target genes : 19 - Drug target pathways : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00630942 (ClinicalTrials.gov)	February 2003	27/2/2008	Minocycline in Primary Sclerosing Cholangitis (PSC)	Open Label Pilot Study Evaluating Minocycline in Patients With Primary Sclerosing Cholangitis (PSC)	Primary Sclerosing Cholangitis	Drug: Minocycline	Mayo Clinic	NULL	Completed	18 Years	75 Years	Both	16	Phase 1	United States

162. Pemphigoid

---

Clinical trials : 83 /  Drugs : 128 - (DrugBank : 51) / Drug target genes : 33 - Drug target pathways : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-TRC-12003592	2011-08-01	2012-12-30	Use of Tripterygium glycosides and Nicotinamide plus Minocycline for the Treatment of bullous pemphigoid: A multicenter,randomized and controlled clinincal trial	Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases	Bullous pemphigoid	Tripterygium glycosides group:Take tripterygium glycosides orally at 20 mg, 3 times a day;Nicotinamide plus Minocycline group:Take nicotinamide at 500 mg, 3 times a day and minocycline 100 mg, twice a day.;	Institute of dermatology, Chinese Academy of Medical Sciences	NULL	Completed	18		Both	Tripterygium glycosides group:100;Nicotinamide plus Minocycline group:100;		China

201. Angelman syndrome

---

Clinical trials : 24 /  Drugs : 35 - (DrugBank : 9) / Drug target genes : 22 - Drug target pathways : 20

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02056665 (ClinicalTrials.gov)	January 2014	5/2/2014	Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome	Randomized Clinical Trial, Placebo Compared to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome	Angelman Syndrome	Drug: MINOCYCLINE;Drug: PLACEBO (for Minocycline)	Puerta de Hierro University Hospital	NULL	Completed	6 Years	30 Years	Both	32	Phase 2	Spain
2	EUCTR2013-002154-67-ES (EUCTR)	26/12/2013	16/09/2013	STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY)	RANDOMIZED CLINICAL TRIAL, PLACEBO COMPARED TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY) - A-MANECE	Angelman Syndrome MedDRA version: 16.0;Level: PT;Classification code 10049004;Term: Angelman's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Aknemin 50 INN or Proposed INN: MINOCYCLINE Other descriptive name: MINOCYCLINE HYDROCHLORIDE	Dra. Cristina Avendaño Solá	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Spain
3	NCT01531582 (ClinicalTrials.gov)	April 2012	5/2/2012	Minocycline in the Treatment of Angelman Syndrome	The Efficacy of Minocycline in the Treatment of Angelman Syndrome	Angelman Syndrome	Drug: minocycline	University of South Florida	NULL	Active, not recruiting	4 Years	12 Years	Both	25	N/A	United States

206. Fragile X syndrome

---

Clinical trials : 104 /  Drugs : 87 - (DrugBank : 32) / Drug target genes : 54 - Drug target pathways : 79

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02680379 (ClinicalTrials.gov)	March 2016	25/1/2016	Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome	A Pilot Study Exploring the Safety and Synergistic Effect of a Minocycline/Lovastatin Combined Treatment on the Behavior of Individuals With Fragile X Syndrome; Validation of New Biochemical and Neurophysiological Markers (LovaMiX)	Fragile X Syndrome	Drug: Minocycline, then Minocycline/Lovastatin;Drug: Lovastatin, then Minocycline/Lovastatin	Université de Sherbrooke	FRAXA Research Foundation	Completed	8 Years	45 Years	All	22	Phase 2	Canada
2	NCT02998151 (ClinicalTrials.gov)	January 2016	1/12/2016	Neurophysiological and Acute Pharmacological Studies in FXS Patients	Neurophysiological and Acute Pharmacological Studies in FXS Patients	Fragile X Syndrome	Drug: Acamprosate;Drug: Lovastatin;Drug: Minocycline;Drug: Placebo;Drug: Baclofen	Children's Hospital Medical Center, Cincinnati	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	15 Years	55 Years	All	29	Early Phase 1	United States
3	NCT01053156 (ClinicalTrials.gov)	January 2010	19/1/2010	Trial of Minocycline to Treat Children With Fragile X Syndrome	Randomized Double-Blind Controlled Cross Over Trial of Minocycline in Children With Fragile X Syndrome	Fragile X Syndrome	Drug: minocycline hydrochloride;Drug: Placebo	University of California, Davis	The National Fragile X Foundation	Completed	42 Months	16 Years	All	66	N/A	United States
4	NCT00858689 (ClinicalTrials.gov)	October 2007	9/3/2009	Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome	Add-on Pilot Trial of Minocycline in Fragile X Syndrome	Fragile X Syndrome	Drug: Minocycline	FRAXA Research Foundation	Fragile X Research Foundation of Canada	Completed	13 Years	35 Years	All	20	N/A	Canada

280. Huge arteriovenous malformation with cervicofacial or limb lesion

---

Clinical trials : 25 /  Drugs : 29 - (DrugBank : 15) / Drug target genes : 14 - Drug target pathways : 153

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00243893 (ClinicalTrials.gov)	July 2004	24/10/2005	Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms	Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms	Aneurysms;Arteriovenous Malformations	Drug: minocycline;Drug: doxycycline	University of California, San Francisco	National Institute of Neurological Disorders and Stroke (NINDS)	Completed	13 Years	80 Years	Both	26	Phase 1	United States

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03489629 (ClinicalTrials.gov)	April 3, 2018	29/3/2018	STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)	STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)	Cystic Fibrosis	Drug: Trimethoprim Sulfamethoxazole (TMP/SMX);Drug: Minocycline;Drug: Mupirocin;Drug: Chlorhexidine Gluconate;Behavioral: Environmental Decontamination	University of North Carolina, Chapel Hill	University of Washington;Cook Children's Medical Center;Indiana University;University of Michigan;University of Texas Southwestern Medical Center;St. Louis Children's Hospital	Recruiting	2 Years	45 Years	All	42	Phase 2	United States
2	EUCTR2013-000219-25-IT (EUCTR)	18/07/2013	12/04/2018	MRSA study.	Early eradication of S. Aureus (MRSA) in patients with cystic fibrosis: a randomized multicenter study.	Patients affected by cystic fibrosis and who present an initial infection of MRSA.;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]	Product Name: Rifampin INN or Proposed INN: RIFAMPICIN Product Name: Trimethoprim-sulfamethoxazole INN or Proposed INN: SULFAMETHOXAZOLE Other descriptive name: TRIMETHOPRIM Product Name: minocycline Other descriptive name: MINOCYCLINE HYDROCHLORIDE	AOU Meyer	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	Italy
3	NCT01349192 (ClinicalTrials.gov)	April 2011	4/5/2011	Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)	Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)	Cystic Fibrosis;Methicillin-resistant Staphylococcus Aureus	Drug: Rifampin;Drug: Trimethoprim/Sulfamethoxazole;Drug: Minocycline;Drug: Mupirocin;Drug: chlorhexidine gluconate oral rinse;Drug: 2% Chlorhexidine solution wipes;Behavioral: Environmental Decontamination	University of North Carolina, Chapel Hill	CF Therapeutics Development Network Coordinating Center;Seattle Children's Hospital;Washington University School of Medicine;University of Washington;University of Colorado, Denver;Baylor College of Medicine;University of Alabama at Birmingham;Cook Children's Medical Center;University of Michigan;University of Florida;University of Texas Southwestern Medical Center;Children's Hospital Medical Center, Cincinnati;St. Louis Children's Hospital	Terminated	4 Years	45 Years	All	47	Phase 2	United States

Back to top